Avience Biomedicals Announces Revised Consolidated Financial Results, Appoints Secretarial Auditor, and Details IPO Proceeds
Avience Biomedicals Limited, formerly Avience Biomedicals Pvt. Ltd., has reported its revised consolidated financial results for the year ended March 31, 2026. The company also announced the appointment of a new Secretarial Auditor and confirmed the completion of its Initial Public Offering (IPO).The Board of Directors meeting on August 25, 2026, approved several key corporate actions. M/s. G.R. Gupta & Associates, practicing Company Secretaries, were appointed as the Secretarial Auditor of the company for a term of five consecutive financial years, commencing from FY 2026-27 and ending with FY 2030-31. Furthermore, the Board approved the payment of sitting fees amounting to ₹1,000/- per meeting for the Independent/Non-Executive Directors, effective from July 1, 2026.
The company’s consolidated financial results for the period ended March 31, 2026, were reviewed by the Audit Committee and audited by M/s. Haribhakti & Co LLP. The company declared an Unmodified Audit Opinion on the Audited Consolidated Financial Statements for the financial year.
Financial Highlights and Audit Details
During the reporting period, the company successfully completed an Initial Public Offering (IPO) of 1,453,800 equity shares, with a face value of ₹10 each and an issue price of ₹208 per equity share. The net proceeds from the fresh issue of the IPO are designated to fund the capital expenditure required for setting up a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh. The remaining funds are allocated towards working capital requirements and general corporate purposes.The audit also noted that the consolidated financial results include the results of the wholly-owned subsidiary, DR Meditech Surgical & Diagnostics (India) Private Limited.
The company's previously adopted consolidated financial results, which were initially approved on July 16, 2026, were subsequently revised. This revision corrected an inadvertent error in the original financial statements where inter-company balances between the Holding Company and its Subsidiary were not eliminated. This correction resulted in an overstatement of Other Current Liabilities and Short-term Loans and Advances by 337.55 lakhs, though the revision had no impact on the consolidated profit for the period or total equity and net assets.
Consolidated Financial Results Summary
The consolidated financial statements for the year ended March 31, 2026, as well as the half-year results for March 31, 2026, are summarized below. All figures are in Rupees Lakhs.Consolidated Statement of Financial Results
| Particulars | 31-Mar-2026 (Audited) | 30-Sep-2025 (Audited) | 31-Mar-2025 (Audited) |
|---|---|---|---|
| Revenue from operations | 2,568.65 | 2,681.93 | 2,447.04 |
| Other Income | 22.98 | 5.94 | 45.59 |
| Total Income | 2,591.63 | 2,687.87 | 2,492.63 |
| Total expenses | 1,955.13 | 2,077.79 | 1,902.31 |
| Profit before tax | 636.50 | 610.08 | 590.33 |
| Profit for the period after minority interest | 421.50 | 453.78 | 426.92 |
Consolidated Balance Sheet (Extract)
| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Long term Borrowings | 1,322.87 | 984.95 |
| Non current liabilities | 1,157.48 | 1,023.68 |
| Current liabilities | 2,958.09 | 2,159.18 |
| Total Equity and Liabilities | 7,456.84 | 5,648.84 |
| Inventories (Current Assets) | 1,717.53 | 1,307.12 |
| Trade receivables (Current Assets) | 2,101.72 | 1,721.06 |
| Total Current Assets | 4,316.35 | 3,717.24 |
Consolidated Statement of Cash Flows
| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Cash generated from operations | 877.92 | 418.12 |
| Net cash used in investing activities | (1,326.94) | (953.91) |
| Net cash generated from financing activities | 541.81 | 1,020.89 |
| Net decrease in cash and cash equivalents | (194.51) | 406.41 |
AVIENCE Stock Price Movement
On Tuesday, shares of Avience Biomedicals Limited gained sharply, closing at ₹280.20 after rallying 4.92%. The stock saw brisk activity, trading 65,400 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: